Everolimus-d4 (Synonyms: RAD001-d4; SDZ-RAD-d4) |
カタログ番号GC47328 |
エベロリムス-d4 (RAD001-d4) は、エベロリムスとラベル付けされた重水素です。エベロリムス (RAD001) は、ラパマイシン誘導体であり、強力で選択的な経口活性 mTOR1 阻害剤です。エベロリムスは FKBP-12 に結合して免疫抑制複合体を生成します。エベロリムスは、腫瘍細胞の増殖を阻害し、細胞のアポトーシスとオートファジーを誘導します。エベロリムスには強力な免疫抑制作用と抗がん作用があります。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1338452-54-2
Sample solution is provided at 25 µL, 10mM.
Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.1,2 It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.2 Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.3,4 It also acts as an immunosuppressive agent in the context of organ transplantation.
1.Zeng, Z., Sarbassov, D.D., Samudio, I.J., et al.Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood109(8)3509-3512(2007) 2.Lebwohl, D., Anak, Ö., Sahmoud, T., et al.Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesAnn. N.Y. Acad. Sci.129114-32(2013) 3.Yunokawa, M., Koizumi, F., Kitamura, Y., et al.Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cellsCancer Sci.103(9)1665-1671(2012) 4.Gurk-Turner, C., Manitpisitkul, W., and Cooper, M.A comprehensive review of everolimus clinical reports: A new mammalian target of rapamycin inhibitorTransplantation94(7)659-668(2012)
Average Rating: 5
(Based on Reviews and 13 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *